Home Webinars IPO roadshow presentation – webinars and in-person JSE presentation – SENS

IPO roadshow presentation – webinars and in-person JSE presentation – SENS

0
                            

IPO roadshow presentation – webinars and in-person JSE presentation

CILO CYBIN HOLDINGS LIMITED
(Incorporated in South Africa)
(Registration number 2022/320351/06)
Ordinary Shares Share code: CCC ISIN: ZAE000310397
(“the Company”)

IPO ROADSHOW PRESENTATION – WEBINARS AND IN-PERSON JSE PRESENTATION

Further to the Exchange News Service of the JSE Limited announcement on 12 September where Cilo Cybin
Holdings Limited informed the market of its intention to raise a Minimum Amount of R500 million by means of an
IPO and list on the JSE main board, the Company would like to invite interested investors to register on their website
at https://www.cilocybin.com for a roadshow presentation via webinar or to attend an in-person presentation at the
JSE Auditorium. RSVP on the website for the in-person registration.

Cilo Cybin Holdings Limited was incorporated by the Founder, Gabriel Theron, for the purposes of being listed on
the Main Board of the JSE with effect from the commencement of trade on Monday, 14 November 2022, as a SPAC
to pursue acquisitions of, and investments in, commercial enterprises operating in the Biotech, Biohacking or
Pharmaceutical sector that will enable it to develop and expand methodologies by utilising Artificial Intelligence (AI)
and expertise of medical specialists to deliver holistic and individualised solutions to customers to better their health,
performance and increase their longevity. The Prospectus and a teaser document with a short introduction are
available on the website.

The industries Cilo Cybin envisions to participate in include Biotech, Cannabis, Psychedelics, wearable devices and
custom nutrition. The Company has identified potential opportunities to acquire several assets located in South
Africa and United States of America (which are still subject to shareholder approval). One of these assets are Cilo
Cybin Pharmaceutical Proprietary Limited (“CCP”). Gabriel Theron is also the founder and main shareholder in CCP.
CCP has a state-of-the-art cultivation, manufacturing and packaging facility in Midrand. The vision of the Company,
from the outset, was not to sell cannabis flower, as a final product but rather processed products. CCP holds a
GACP license from the regulator in South Africa, SAHPRA to cultivate cannabis and a second license for the
manufacturing facility, making CCP the first Company in South Africa to have both GACP and GMP cannabis
licenses in one Company. CCP develops, manufactures and distributes its own products.

Globally cannabis, psychedelics and overall physical and mental health have become high growth, high margin,
attractive businesses to invest in. CCP has been operating in this sector since 2018 (for 4 years) formulating and
producing its own branded product and are leaders in this market segment.

Gabriel Theron, the founder of the Company will be presenting the investment case for the Company at
these events.

Please book for the following events on the Cilo Cybin website:

DATES AND TIMES WEBINARS

2022 TIME
Tuesday, 18 October Evening, 19:00 – 20:00
Thursday, 20 October Morning, 8:00 – 9:00
Wednesday, 26 October Morning, 8:00 – 9:00
Book online at www.cilocybin.com

DATE FOR IN-PERSON PRESENTATION AT JSE AUDITORIUM

2022 TIME
Wednesday, 26 October Evening, 17:30 for 18:00
RSVP online at www.cilocybin.com

Midrand
18 October 2022

Sponsor
DEA-RU Proprietary Limited

Date: 18-10-2022 08:15:00
Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited (‘JSE’).
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct,
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
information disseminated through SENS.